MedTrace Logo

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

NCT04887870 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-10-10

No results posted yet for this study

Summary

A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies

Conditions

  • Advanced or Metastatic Solid Malignancies

Interventions

DRUG

Sitravatinib

Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.

DRUG

Nivolumab

Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

DRUG

Pembrolizumab

Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody

DRUG

Enfortumab Vedotin-Ejfv

Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)

DRUG

Ipilimumab

Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody

Sponsors & Collaborators

  • Mirati Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-29
Primary Completion
2025-04-21
Completion
2025-09-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04887870 on ClinicalTrials.gov